Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Pfizer Inc. : Study Shows Positive Results for Pfizer's Lyrica Treatment for Fibromyalgia

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/19/2012 | 02:40pm CEST
   By Saabira Chaudhuri 
 

Pfizer Inc. (>> Pfizer Inc.) said results of a late-stage study of its pregabalin controlled-release formulation as a treatment for fibromyalgia were positive.

The drug company said top-line results of a Phase 3 study evaluating pregabalin controlled-release formulation, also known as Lyrica, in patients with fibromyalgia indicated that it had a statistically significant positive effect compared with a placebo with regards to time to loss of therapeutic response.

Pfizer described fibromyalgia as a common pain condition in the U.S. affecting more than five million Americans and characterized by chronic widespread pain and tenderness lasting for three or more months.

The most recent study is the second of three Phase 3 studies of the pregabalin controlled-release formulation, which Pfizer said will determine the potential use of pregabalin as a once-a-day therapy.

Last week, Pfizer had revealed that a Phase 3 study showed Lyrica as a potential epilepsy treatment didn't meet the primary endpoint for a change in seizure frequency. Monday, the drug company noted that the final study in post-herpetic neuralgia is ongoing.

"Collectively, the results of these controlled-release studies will allow us to better understand the potential of a once-a-day pregabalin treatment regimen," said Steven J. Romano, head of Pfizer's Global Primary Care Business Unit's Medicines Development Group. "Reducing the number of times patients need to take their medicine per day while maintaining the same efficacy and safety profile could potentially provide a greater convenience and the potential to enhance treatment adherence and outcomes."

Shares edged up 12 cents to $23.98 in recent premarket trading. The stock has risen 22% in the past year.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER INC
03/30 BRISTOL MYERS SQUIBB : and Pfizer Present Large Real-World Observational Analysi..
03/30 PFIZER : Service expansions one step in fulfilling pledge to grow capabilities
03/29 PFIZER : XELJANZ (tofacitinib citrate) licensed for use in the UK for the treatm..
03/29 PFIZER : Confirms MHRA Review of Sildenafil 50mg for Reclassification as Non-Pre..
03/29 PFIZER : EC approves Pfizer`s Xeljanz to treat rheumatoid arthritis in EU
03/29 GLAXOSMITHKLINE : Selling GSK would be a mistake
03/28 GLAXOSMITHKLINE : What to do with GSK
03/28 PFIZER : XELJANZ (tofacitinib citrate) Receives Marketing Authorisation In The E..
03/28 PFIZER : MSF launches new strategies to help gov'ts buy 'expensive' pneumonia va..
03/28 TALK OF BRISTOL-MYERS SQUIBB CO (NYS : BMY) Acquisition By Pfizer Inc. (NYSE:PFE..
More news
Sector news : Pharmaceuticals - NEC
03/30 China's Creat makes 1.2 billion euro bid for German blood plasma firm
03/30DJOXFORD BIOMEDICA : Hails U.S. Regulatory Boost for Leukemia Treatment
03/29 FDA, Mylan silence on generic Advair may be good news for GSK
03/29 British business navigates rocky path to Brexit
03/29 ConvaTec's majority investors raise $1.2 billion via stake sale
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2015 Update
2015 Antibiotics Stocks To Benefit From 21st Century Cures Act
2015 ISIS PHARMA STOCK DROPS ON GOOD NEWS : Re-Evaluating The Bull Case
2015 DOW DOGS : 14.63% More Returns From 5 Lowest Priced As Of August 6 Per indexArb
2015 Pfizer's GL-2045 an Orphan Drug for CIDP
Advertisement
Financials ($)
Sales 2017 53 399 M
EBIT 2017 20 360 M
Net income 2017 13 219 M
Debt 2017 23 547 M
Yield 2017 3,73%
P/E ratio 2017 14,75
P/E ratio 2018 13,90
EV / Sales 2017 4,27x
EV / Sales 2018 4,01x
Capitalization 204 439 M
More Financials
Chart PFIZER INC
Duration : Period :
Pfizer Inc Technical Analysis Chart | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 38,1 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Mikael Dolsten President-Worldwide Research & Development
Ole Isacson Chief Scientific Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC13.96%204 439
JOHNSON & JOHNSON9.07%338 645
ROCHE HOLDING LTD.8.81%221 440
PFIZER INC.5.70%204 439
NOVARTIS AG-0.47%197 239
MERCK & CO., INC.8.10%174 728
More Results